Biothera Pharmaceuticals, Inc. is advancing Imprime PGG, a unique cancer immunotherapy, through Phase 2 clinical trials in multiple cancer indications. While cancers can actively avoid detection by the immune system, Imprime PGG works as an immunological “ignition switch” to activate a host of anti-tumor immune system responses. These robust, coordinated innate and adaptive immune responses can enhance the therapeutic efficacy of immune checkpoint inhibitors and other monoclonal antibodies. Studies in over 400 patients have demonstrated clinical proof of concept and a favorable safety profile for Imprime PGG in combination with anti-cancer antibodies. Biothera Pharmaceuticals is developing Imprime PGG, the first systemically administered Pathogen Associated Molecular Patterning (PAMP) drug, in Phase 2 combination trials with checkpoint inhibitors. Patient recruitment is underway for studies in melanoma, triple negative breast cancer and non-small cell lung cancer. A clinical study in head and neck cancer is scheduled to begin in the second quarter. Significant milestones, including response, safety and biomarker data, are expected through 2017-18.
About Biothera Pharmaceuticals
Biothera Pharmaceuticals has partnered with leading pharmaceutical companies and research organizations to advance Imprime PGG and cancer immunotherapy. The Company entered into clinical research agreements with Merck to evaluate Imprime PGG and pembrolizumab (KEYTRUDA®) in multiple indications. Learn More
Biothera Pharmaceuticals was recently featured in BioWorld Today, which reported on the Company’s unique PAMP technology, clinical development plans with checkpoint inhibitors and path to FDA approval for Imprime PGG. Learn More